MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-14-2022
Opiant Pharmaceuticals Cash Conversion Cycle 2011-2026 | OPNT
Annual Cash Conversion Cycle Opiant Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 84.9 | -64.9 | 2.77 | -160 | - | - | - | - | - | 91.2 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 91.2 | -160 | -9.24 |
Quarterly Cash Conversion Cycle Opiant Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 624 | 79.5 | 181 | - | 70.2 | 62.1 | 104 | - | 89.3 | 129 | 172 | - | 31.9 | 97.2 | 98.3 | - | 93.8 | 130 | 434 | 78.9 | 48.5 K | 283 | 24.3 K | 4.65 | 41.2 | 4.09 | 12.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 48.5 K | 4.09 | 3.29 K |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Veracyte
VCYT
|
32.2 | $ 30.92 | -5.73 % | $ 2.43 B |  USA |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M |  Israel |
 |
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
-54.4 | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
85.5 | - | - | $ 789 M | USA |
 |
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
72.3 | $ 12.67 | -9.24 % | $ 1.92 B | USA |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Alnylam Pharmaceuticals
ALNY
|
46.6 | $ 321.51 | -2.03 % | $ 42.1 B | USA |
 |
BioDelivery Sciences International
BDSI
|
340 | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
52.4 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
3.1 | - | - | $ 3.74 B | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
-193 | $ 1.09 | - | $ 22.4 M | Israel |
 |
Equillium
EQ
|
16.6 | $ 1.91 | -7.28 % | $ 109 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
205 | $ 19.46 | -0.36 % | $ 910 M | USA |
 |
Amarin Corporation plc
AMRN
|
213 | $ 14.23 | -2.97 % | $ 5.91 B |  Irlanda |
 |
CRISPR Therapeutics AG
CRSP
|
1.1 K | $ 45.99 | -3.28 % | $ 4.14 B |  Schweiz |
 |
Arbutus Biopharma Corporation
ABUS
|
50 | $ 4.33 | -2.81 % | $ 830 M | Canada |
 |
Brickell Biotech
BBI
|
149 | - | -5.38 % | $ 6.06 M | USA |